Krystal Biotech (KRYS) Gross Margin (2023 - 2026)

Krystal Biotech (KRYS) posted quarterly Gross Margin of 94.6% for Q2 2026, up 206.0% year-over-year from 30.92% in Q2 2025, and little changed on a QoQ basis from 94.57% in Q1 2026.

Krystal Biotech (KRYS) Gross Margin (2023 - 2026) Analysis & Trends

Krystal Biotech has reported Gross Margin for 4 years, with the latest figure at 94.6% in Q2 2026.

  • Gross Margin for Q2 2026 came in at 94.6%, up 206.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 94.64% (up 127.0% YoY), and the FY2025 annual result was 94.08%, up 98.0% from the prior year.
  • Gross Margin steadied at 94.6% in Q2 2026, from 94.57% in the prior quarter.
  • Over five years, Gross Margin peaked at 97.39% in Q3 2023 and troughed at 91.45% in Q2 2024.
  • A 4-year average of 94.07% and a median of 94.43% in 2026 frame the typical range for Gross Margin.
  • The widest annual swing landed in 2024, when Gross Margin slumped 537 bps; it then surged 361 bps in 2025.
  • A 4-year view of Gross Margin shows it stood at 93.19% in 2023, then climbed by 1 bps to 94.57% in 2024, then declined by 1 bps to 93.85% in 2025, then rose by 1 bps to 94.6% in 2026.
  • Per Business Quant data, the three most recent Gross Margin figures were 94.6% in Q2 2026, 94.57% in Q1 2026, and 93.85% in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 85.33%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 91.59%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 90.68%
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 89.76%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 60,631,834.75%
7 Royalty Pharma 33.72 Bn 35.84 Bn - -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 76.90%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 84.20%
10 Krystal Biotech 9.83 Bn 8.99 Bn 112.79 Mn 94.60%

Historic Data

Download Data
DateValue
Jun 30, 2026 94.60%
Mar 31, 2026 94.57%
Dec 31, 2025 93.85%
Sep 30, 2025 95.64%
Jun 30, 2025 92.54%
Mar 31, 2025 94.30%
Dec 31, 2024 94.57%
Sep 30, 2024 92.03%
Jun 30, 2024 91.45%
Mar 31, 2024 94.65%
Dec 31, 2023 93.19%
Sep 30, 2023 97.39%